Maricel Apuli Sells 2,000 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CAO Maricel Apuli sold 2,000 shares of BridgeBio Pharma stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $71.58, for a total transaction of $143,160.00. Following the completion of the sale, the chief accounting officer directly owned 134,115 shares in the company, valued at $9,599,951.70. This represents a 1.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maricel Apuli also recently made the following trade(s):

• On Tuesday, February 17th, Maricel Apuli sold 510 shares of BridgeBio Pharma stock. The shares were sold at an average price of $74.31, for a total transaction of $37,898.10.

BridgeBio Pharma Stock Down 0.3%

Shares of NASDAQ BBIO opened at $68.78 on Wednesday. The company’s 50-day simple moving average is $71.29 and its 200-day simple moving average is $71.14. BridgeBio Pharma, Inc. has a 52-week low of $31.77 and a 52-week high of $84.94. The firm has a market cap of $13.47 billion, a price-to-earnings ratio of -18.20 and a beta of 1.02.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The company had revenue of $154.18 million for the quarter, compared to analysts’ expectations of $150.71 million. The firm’s revenue was up 2521.2% on a year-over-year basis. During the same period in the previous year, the business posted ($1.40) EPS. Equities research analysts anticipate that BridgeBio Pharma, Inc. will post -2.05 EPS for the current fiscal year.

Hedge Funds Weigh In On BridgeBio Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BBIO. Aster Capital Management DIFC Ltd acquired a new stake in shares of BridgeBio Pharma in the 3rd quarter worth $31,000. Harvest Fund Management Co. Ltd acquired a new position in shares of BridgeBio Pharma during the 3rd quarter valued at about $34,000. Jones Financial Companies Lllp purchased a new stake in shares of BridgeBio Pharma in the first quarter valued at about $35,000. First Horizon Corp purchased a new stake in shares of BridgeBio Pharma in the third quarter valued at about $36,000. Finally, Huntington National Bank increased its position in BridgeBio Pharma by 111.7% during the third quarter. Huntington National Bank now owns 743 shares of the company’s stock worth $39,000 after purchasing an additional 392 shares during the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Wells Fargo & Company raised their target price on BridgeBio Pharma from $88.00 to $98.00 and gave the company an “overweight” rating in a research report on Friday, February 13th. Royal Bank Of Canada started coverage on BridgeBio Pharma in a research note on Thursday, April 9th. They issued an “outperform” rating and a $100.00 price objective for the company. TD Cowen restated a “buy” rating on shares of BridgeBio Pharma in a report on Monday, January 12th. Truist Financial lifted their target price on shares of BridgeBio Pharma from $95.00 to $102.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Finally, Raymond James Financial set a $89.00 target price on shares of BridgeBio Pharma and gave the stock an “outperform” rating in a report on Thursday, February 12th. Twenty-four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $87.71.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.